EP1849470A1 — Anticancer drug containing alpha, alpha, alphatrifluorothymidine and thymidine phosphorylase inhibitor
Assigned to Taiho Pharmaceutical Co Ltd · Expires 2007-10-31 · 19y expired
What this patent protects
A cancer therapeutic drug enhanced efficacy and safety is provided. The cancer therapeutic drug, which is a composition containing α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1 : 0.5, and which is ora…
USPTO Abstract
A cancer therapeutic drug enhanced efficacy and safety is provided. The cancer therapeutic drug, which is a composition containing α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1 : 0.5, and which is orally administered to a patient in need thereof at a dose, as a dose of FTD, of 20 to 80 mg/m 2 /day twice daily to four times daily.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.